NIOX Group (LON:NIOX) Stock Price Down 1% – Here’s What Happened

NIOX Group Plc (LON:NIOX) was down 1% on Monday . The stock traded as low as GBX 56.48 and last traded at GBX 57. 575,719 shares traded hands during mid-day trading, a decline of 32% from the average daily volume of 845,308 shares. The stock had previously closed at GBX 57.60.

NIOX Group Stock Performance

The company has a debt-to-equity ratio of 1.36, a current ratio of 3.81 and a quick ratio of 1.94. The stock has a 50-day simple moving average of GBX 60.53 and a 200 day simple moving average of GBX 63.08. The company has a market capitalization of £244.94 million, a PE ratio of 35.49 and a beta of 0.92.

NIOX Group (LON:NIOX) last released its quarterly earnings results on Tuesday, March 24th. The company reported GBX 4.03 EPS for the quarter. NIOX Group had a net margin of 14.37% and a return on equity of 10.14%. Equities analysts anticipate that NIOX Group Plc will post 1.1658256 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, insider Sarah Duncan bought 34,127 shares of NIOX Group stock in a transaction on Friday, May 29th. The shares were bought at an average cost of GBX 59 per share, for a total transaction of £20,134.93. Also, insider Jonathan Emms sold 69,494 shares of the firm’s stock in a transaction dated Monday, April 20th. The stock was sold at an average price of GBX 58, for a total transaction of £40,306.52. In the last ninety days, insiders have purchased 102,805 shares of company stock worth $5,996,817 and have sold 662,056 shares worth $37,453,394. 5.11% of the stock is owned by company insiders.

About NIOX Group

NIOX Group plc is a medical technology company focused on improving the lives of millions of people suffering from respiratory health issues globally. NIOX develops and markets innovative, non-invasive diagnostic products for chronic airway diseases, primarily asthma and COPD. Its lead product, NIOX VERO®, enables the accurate measurement of fractional exhaled nitric oxide (FeNO), an established biomarker for airway inflammation, supporting better diagnosis, monitoring and management of asthma and COPD in clinical and research settings.

Headquartered in the UK and listed on the London Stock Exchange (ticker: NIOX), the company operates internationally, serving healthcare professionals in over 50 countries.